The financials
Gilead Sciences by the numbers
Gilead Sciences (GILD) reported revenue of $7.80B in Q2 2026 (quarter ended June 30, 2026), up 10% from the same quarter a year earlier. That came with a gross margin of 80% and net loss of $10.5B. For the full year FY2025, revenue was $29.4B (+2.4% year on year) and net income $8.51B. Its largest product in 2026-Q2 was HIV Product Sales at $4.66B, 55% of the disclosed total, just ahead of HIV Products Descovy at 11%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $7.80B | $7.08B | +10% |
| Gross profit | $6.22B | $5.58B | +12% |
| Operating income | −$10.4B | $2.47B | to a loss |
| Net income | −$10.5B | $1.96B | to a loss |
| Diluted EPS | −$8.45 | $1.56 | to a loss |
| Product | Revenue | Share |
|---|---|---|
| HIV Product Sales | $4.66B | 55% |
| HIV Products Descovy | $921M | 11% |
| Oncology Product | $468M | 5.5% |
| Liver Disease | $433M | 5.1% |
| Trodelvy | $307M | 3.6% |
| HIV Products Genvoya | $236M | 2.8% |
| HIV Products Yeztugo | $223M | 2.6% |
| Royalty Contract And Other | $176M | 2.1% |
| HIV Products Odefsey | $171M | 2.0% |
| Cell Therapy Products Total Cell Therapy Product Sales | $161M | 1.9% |
| Liver Disease Products Livdelzi | $147M | 1.7% |
| Liver Disease Products Sofosbuvir Velpatasvir | $142M | 1.7% |
| Other Products Yescarta | $132M | 1.5% |
| Liver Disease Products Vemlidy | $124M | 1.5% |
| HIV Products Symtuza Revenue Share | $105M | 1.2% |
| Cell Therapy Products Tecartus | $29M | 0.3% |
| Other Products Total Other Product Sales | $26M | 0.3% |
| HIV Products Other HIV | $23M | 0.3% |
| Other Products Other | $22M | 0.3% |
| Liver Disease Products Other Liver Disease | $20M | 0.2% |
| Veklury | $14M | 0.2% |
| Other Products Am Bisome | $4.0M | 0.0% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $8.54B (+17%)
HIV Products Yeztugo grew +1387% year on yearVeklury -73% year on year
Segment Latestquarter on quarteryear on year
- HIV Product Sales$4.66B$4.66BQoQ +16%year on year +14%+16%+14%
- HIV Products Descovy$921.0M$921.0MQoQ +21%year on year +53%+21%+53%
- Oncology Product$468.0M$468.0MQoQ +16%year on year +9.6%+16%+9.6%
- Liver Disease$433.0M$433.0MQoQ +20%year on year +4.8%+20%+4.8%
- Trodelvy$307.0M$307.0MQoQ +21%year on year +37%+21%+37%
- HIV Products Genvoya$236.0M$236.0MQoQ +9.8%year on year -27%+9.8%-27%
- HIV Products Yeztugo$223.0M$223.0MQoQ +41%year on year +1387%+41%+1387%
- Royalty Contract And Other$176.0M$176.0MQoQ +1157%year on year +552%+1157%+552%
- HIV Products Odefsey$171.0M$171.0MQoQ +12%year on year -23%+12%-23%
- Cell Therapy Products Total Cell Therapy Product Sales$161.0M$161.0MQoQ +7.3%year on year -21%+7.3%-21%
- Liver Disease Products Livdelzi$147.0M$147.0MQoQ +28%year on year +99%+28%+99%
- Liver Disease Products Sofosbuvir Velpatasvir$142.0M$142.0MQoQ +0.71%year on year -23%+0.71%-23%
- Other Products Yescarta$132.0M$132.0MQoQ +10%year on year -19%+10%-19%
- Liver Disease Products Vemlidy$124.0M$124.0MQoQ +36%year on year +1.6%+36%+1.6%
- HIV Products Symtuza Revenue Share$105.0M$105.0MQoQ -1.9%year on year +19%-1.9%+19%
- Cell Therapy Products Tecartus$29.0M$29.0MQoQ -3.3%year on year -29%-3.3%-29%
- Other Products Total Other Product Sales$26.0M$26.0MQoQ -43%year on year -50%-43%-50%
- HIV Products Other HIV$23.0M$23.0MQoQ -36%year on year -54%-36%-54%
- Other Products Other$22.0M$22.0MQoQ -44%year on year -50%-44%-50%
- Liver Disease Products Other Liver Disease$20.0M$20.0MQoQ +33%year on year -39%+33%-39%
- Veklury$14.0M$14.0MQoQ -88%year on year -73%-88%-73%
- Other Products Am Bisome$4.0M$4.0MQoQ -43%year on year -43%-43%-43%
Drug Manufacturers - General
Ranks #6 of 16 by Smart Score